General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2′-Modified Nucleotide Analogues

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2006-09-25

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.00433-06PMID 17000745PMCID PMC1693996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibitory Effect of 2′-Substituted Nucleosides on Hepatitis C Virus Replication Correlates with Metabolic Properties in Replicon Cells

  2005cited by this paper
• Challenges and successes in developing new therapies for hepatitis C

  2005cited by this paper
• Replication Fitness and NS5B Drug Sensitivity of Diverse Hepatitis C Virus Isolates Characterized by Using a Transient Replication Assay

  2005cited by this paper
• A Relaxed Discrimination of 2′-O-Methyl-GTP Relative to GTP between de Novo and Elongative RNA Synthesis by the Hepatitis C RNA-dependent RNA Polymerase NS5B*

  2005influential reference
• In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061*

  2005cited by this paper
• Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors.

  2005cited by this paper
• Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro

  2005cited by this paper
• Binding Site Characterization and Resistance to a Class of Non-nucleoside Inhibitors of the Hepatitis C Virus NS5B Polymerase*

  2005cited by this paper
• Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective☆

  2004cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Excision of incorporated nucleotide analogue chain-terminators can diminish their inhibitory effects on viral RNA-dependent RNA polymerases.

  2004cited by this paper
• Mechanistic Basis for Reduced Viral and Enzymatic Fitness of HIV-1 Reverse Transcriptase Containing Both K65R and M184V Mutations*

  2004cited by this paper
• Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.

  2004cited by this paper
• Characterization of the Inhibition of Hepatitis C Virus RNA Replication by Nonnucleosides

  2004cited by this paper
• A Loss of Viral Replicative Capacity Correlates with Altered DNA Polymerization Kinetics by the Human Immunodeficiency Virus Reverse Transcriptase Bearing the K65R and L74V Dideoxynucleoside Resistance Substitutions*

  2004cited by this paper
• Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.

  2004cited by this paper
• The structure of the RNA-dependent RNA polymerase from bovine viral diarrhea virus establishes the role of GTP in de novo initiation.

  2004cited by this paper
• Progress and development of small molecule HCV antivirals.

  2004cited by this paper
• A 7-Deaza-Adenosine Analog Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic Properties

  2004cited by this paper
• The impact of the M184V substitution on drug resistance and viral fitness

  2004cited by this paper
• The impact of the M184V substitution on drug resistance and viral fitness.

  2004cited by this paper
• Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate.

  2004cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation.

  2003cited by this paper
• Multiple interactions within the hepatitis C virus RNA polymerase repress primer-dependent RNA synthesis.

  2003cited by this paper
• Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs*

  2003influential reference
• Arresting Initiation of Hepatitis C Virus RNA Synthesis Using Heterocyclic Derivatives*

  2003cited by this paper
• Resistance Profile of a Hepatitis C Virus RNA-Dependent RNA Polymerase Benzothiadiazine Inhibitor

  2003cited by this paper
• Mechanismof Action and Antiviral Activity of Benzimidazole-Based AllostericInhibitors of the Hepatitis C Virus RNA-Dependent RNAPolymerase

  2003cited by this paper
• Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression.

  2003cited by this paper
• Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro*

  2003influential reference
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides

  2002influential reference
• Hepatitis C virus infection.

  2001cited by this paper
• A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase.

  2001cited by this paper
• A mechanism for initiating RNA-dependent RNA polymerization

  2001cited by this paper
• De Novo Initiation of RNA Synthesis by Hepatitis C Virus Nonstructural Protein 5B Polymerase

  2000cited by this paper
• Template/Primer Requirements and Single Nucleotide Incorporation by Hepatitis C Virus Nonstructural Protein 5B Polymerase

  2000cited by this paper
• De Novo Initiation of RNA Synthesis by the RNA-Dependent RNA Polymerase (NS5B) of Hepatitis C Virus

  2000cited by this paper
• A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.

  1999cited by this paper
• A Recombinant Hepatitis C Virus RNA-Dependent RNA Polymerase Capable of Copying the Full-Length Viral RNA

  1999cited by this paper
• Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus.

  1999cited by this paper
• Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus.

  1999cited by this paper
• Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

  1999cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

  1998cited by this paper
• VMD: visual molecular dynamics.

  1996cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Mechanism of Inhibition of the Active Triphosphate Form of 2′-α-Fluoro,2′-β-bromouridine against Yellow Fever Virus RNA-Dependent RNA Polymerase

  2025cites this paper
• Programmable self-replicating JEV nanotherapeutics redefine RNA delivery in ALS

  2025cites this paper
• Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2

  2022influential citation
• Inhibition of Viral RNA-Dependent RNA Polymerases by Nucleoside Inhibitors: An Illustration of the Unity and Diversity of Mechanisms

  2022cites this paper
• Dissecting nucleotide selectivity in viral RNA polymerases

  2021cites this paper
• IN SILICO ANALYSIS OF NS5B GENE OF HCV GENOTYPE 4 IN NORTH EGYPT

  2020influential citation
• Molecular Characterization of Hepatitis C Virus for Developed Antiviral Agents Resistance Mutations and New Insights into in-silico Prediction Studies

  2020cites this paper
• Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase

  2020cites this paper
• Nucleotide analogues as inhibitors of SARS‐CoV Polymerase

  2020influential citation
• Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects.

  2019cites this paper
• 2′-C-methylated nucleotides terminate virus RNA synthesis by preventing active site closure of the viral RNA-dependent RNA polymerase

  2019cites this paper
• A Structure-Function Diversity Survey of the RNA-Dependent RNA Polymerases From the Positive-Strand RNA Viruses

  2019cites this paper
• Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients

  2018cites this paper
• 5′ UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt

  2018cites this paper
• Structural and Functional Basis of the Fidelity of Nucleotide Selection by Flavivirus RNA-Dependent RNA Polymerases

  2018cites this paper
• Transmission genetics of drug-resistant hepatitis C virus

  2018cites this paper
• Structural Flexibility in HCV NS5B Polymerase and Molecular Modelling of Anti-HCV Drugs

  2018cites this paper
• No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.

  2018cites this paper
• Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors

  2017cites this paper
• The FDA‐approved drug sofosbuvir inhibits Zika virus infection

  2017cites this paper
• A structural view of the RNA-dependent RNA polymerases from the Flavivirus genus.

  2017cites this paper
• In vitro Selection of Resistance to Sofosbuvir in HCV Replicons of Genotype-1 to -6

  2017cites this paper
• Substrate selectivity of Dengue and Zika virus NS5 polymerase towards 2′‐modified nucleotide analogues

  2017influential citation
• HCV Drug Resistance

  2017cites this paper
• Evaluation of Sofosbuvir (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine) as an inhibitor of Dengue virus replication#

  2017cites this paper
• Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients

  2017cites this paper
• Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.

  2016cites this paper
• Modified Nucleoside Triphosphates for In-vitro Selection Techniques

  2016cites this paper
• Effect of Minor Populations of NS5A and NS5B Resistance-Associated Variants on HCV Genotype-3 Response to Daclatasvir plus Sofosbuvir, with or without Ribavirin

  2016cites this paper
• A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin

  2016cites this paper
• Resistance Analyses of Japanese Hepatitis C‐Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies

  2016cites this paper
• Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights

  2016cites this paper
• Computational study on the binding and unbinding mechanism of HCV NS5B with the inhibitor GS-461203 and substrate using conventional and steered molecular dynamics simulations

  2016cites this paper
• Super-resolution light microscopy studies of the organisation and architecture of the hepatitis C virus RNA replication complex

  2016cites this paper
• Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.

  2016cites this paper
• Outcomes of Treatment with Ledipasvir and Sofosbuvir Short Title : Ledipasvir / Sofosbuvir Baseline RASs and Treatment Outcomes

  2016cites this paper
• Overcoming stability challenges in the quantification of tissue nucleotides: determination of 2'-C-methylguanosine triphosphate concentration in mouse liver.

  2015cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1312 Discovery and evaluation of direct acting antivirals against hepatitis C virus

  2015cites this paper
• Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase

  2015cites this paper
• Discovery and evaluation of direct acting antivirals against hepatitis C virus

  2015cites this paper
• Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature

  2015cites this paper
• Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2′-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases

  2015cites this paper
• Structural basis for RNA replication by the hepatitis C virus polymerase

  2015cites this paper
• Emergence of genetically variant Hepatitis C virus population in response to increased antiviral drug pressure, Pakistan

  2014cites this paper
• Inhibitors of the Tick-Borne, Hemorrhagic Fever-Associated Flaviviruses

  2014cites this paper
• Cloning and Molecular Analysis of Hepatitis C Virus (HCV) 1a NS5B from HCV Isolated in Surakarta Indonesia

  2014cites this paper
• Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors

  2014cites this paper
• Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

  2014cites this paper
• Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development.

  2014cites this paper
• Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevance.

  2014cites this paper
• Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus

  2014cites this paper
• Detailed Computational Study of the Active Site of the Hepatitis C Viral RNA Polymerase to Aid Novel Drug Design

  2013cites this paper
• RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs.

  2013cites this paper
• Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution

  2013cites this paper
• Structure of Hepatitis C Virus Polymerase in Complex with Primer-Template RNA

  2012cites this paper
• Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.

  2012cites this paper
• The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance.

  2012influential citation
• Synthesis, in vitro and in silico NS5B polymerase inhibitory activity of benzimidazole derivatives.

  2012cites this paper
• Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.

  2012cites this paper
• HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents.

  2012cites this paper
• Assays for RNA synthesis and replication by the hepatitis C virus

  2012cites this paper
• Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus

  2012cites this paper
• 1 2 3 4 5 6 Genotype and Subtype Profiling of PSI-7977 as a 7 Nucleotide Inhibitor of Hepatitis C Virus 8 9 Running title : PSI-7977 as a Nucleotide Inhibitor of HCV 10 11

  2012cites this paper
• Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates

  2012influential citation
• Enzymatic Recognition of 2′‐Modified Ribonucleoside 5′‐Triphosphates: Towards the Evolution of Versatile Aptamers

  2012cites this paper
• Nucleotide Prodrugs for HCV Therapy

  2011cites this paper
• Nucleic Acids as Biomolecular Probes: Synthesis, Substrate, and Antiviral Properties

  2011cites this paper
• Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors

  2011cites this paper
• Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients.

  2011cites this paper
• Recent Advances in Hepatitis C Therapies

  2010cites this paper
• Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B

  2010cites this paper
• Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7-deaza-adenosine triphosphate.

  2010cites this paper
• Why No Vaccine For Hepatitis C Virus Yet.

  2009cites this paper
• Procédé permettant la synthèse enzymatique de l'arn modifié chimiquement

  2009cites this paper
• Hepatitis: HCV variability, the immune system and resistance to antiviral drugs

  2009cites this paper
• Antiviral agents acting as DNA or RNA chain terminators.

  2009cites this paper
• Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.

  2009cites this paper
• Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step.

  2009cites this paper
• Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs

  2009cites this paper
• Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women.

  2009cites this paper
• Approaches for the development of antiviral compounds: the case of hepatitis C virus.

  2009cites this paper
• The emerging field of HCV drug resistance.

  2008cites this paper
• Short peptide nucleic acids (PNA) inhibit hepatitis C virus internal ribosome entry site (IRES) dependent translation in vitro.

  2008cites this paper
• Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

  2008cites this paper
• Effects of Mutagenic and Chain-Terminating Nucleotide Analogs on Enzymes Isolated from Hepatitis C Virus Strains of Various Genotypes

  2008cites this paper
• Resistance mechanisms in HCV: from evolution to intervention

  2008cites this paper
• Phosphoramidate dinucleosides as hepatitis C virus polymerase inhibitors.

  2008cites this paper
• Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.

  2008cites this paper
• The emerging field of HCV drug resistance

  2008cites this paper
• Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)

  2007cites this paper
• Evaluation systems for anti-HCV drugs.

  2007cites this paper
• Specific targeted antiviral therapy for hepatitis C

  2007cites this paper
• Status Presens of Antiviral Drugs And Strategies: Part I: DNA Viruses and Retroviruses

  2007cites this paper
• Pyrophosphorolytic Excision of Nonobligate Chain Terminators by Hepatitis C Virus NS5B Polymerase

  2007influential citation
• Is reduction of viral fitness a valid antiviral approach

  2007cites this paper
• Acta Universitatis Upsaliensis Uppsala 2015

  year unknowncites this paper
• Effects of Mutagenic and Chain Terminating Nucleotide Analogs on Enzymes Isolated from Various Hepatitis C Virus Genotypes

  year unknowncites this paper